These results were not yet peer reviewed or published, and Eli Lilly will likely apply for FDA-approval in 2027
Semaglutide targets GLP-1 receptors alone
Studies have shown that patients on these medications, combined with lifestyle changes, can achieve substantial weight loss, often in the range of 15% to over 20% of their total body weight, making them a powerful tool in the fight against obesity
Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher
Here's the catch: your body's natural GLP-1 has an extremely short lifespan
This same group of researchers and Lindsay Zasadzinski, MPH, of the American Medical Association (AMA), teamed up for another study that was published in the Journal of the American Heart Association to examine how spending on these drugs varied by state